Elekta has on January 24, 2008, repurchased 100,000 B shares at an average price of SEK 104.79. Elekta’s current holding of own shares (treasury stock) amounts to 1 730 871 B-shares, including 1,630,871 B shares, which are in the process of being cancelled according to the decision by the AGM on September 25.Stockholm Sweden — Wednesday, January 23, 2008
The total number of shares in Elekta as of December 31, 2007 amounts to 93,903,316 divided between 3,562,500 A shares and 90,340,816 B shares.
The repurchases currently being carried out follows the Board’s decision on January 23, 2008, to mandate executive management to initiate on appropriate occasions the repurchase of shares amounting up to SEK 100 M, but maximized to 1,200,000 shares.
For information regarding implementation of additional purchases within this mandate, Elekta offers reference continually to http://omxgroup.com/nordicexchange.
Purchases will be made on the Nordic Exchange and at a price within the registered price interval at the time of each purchase. Purchases may be made during the period until the next Annual General Meeting. Elekta’s Board intends to suggest to the AGM that repurchased shares are cancelled.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.
Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.
Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb.
Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37
Time zone: CET: Central European
Michelle Lee, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447
Time zone: EDT: Eastern Daylight Time